Compare Inovio Pharmaceuticals Inc (INO) vs Nordic American Tankers Limited Common Stock (NAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nordic American Tankers Limited Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $103.19M), while Nordic American Tankers Limited Common Stock trades at $8.2 (market cap $1.86B). The key difference: Nordic American Tankers Limited Common Stock is far larger — about 18× Inovio Pharmaceuticals Inc's market cap, and Nordic American Tankers Limited Common Stock pays a 12.29% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Nordic American Tankers Limited Common Stock for 0 Days on average.
| INO | NAT | |
|---|---|---|
Market Cap | $103.19M | $1.86B |
Volume | 8,461,580 | 5,330,493 |
Sector | Health | Industrials |
52-Week High | $2.60 | $8.79 |
52-Week Low | $0.66 | $3.26 |
Typical Hold Time | 43 Days | 0 Days |
Enterprise Value | $74.52M | $2.13B |
Dividend Yield | — | 12.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $0.986, down 10.77% in the last session, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis. Analyst consensus remains positive with a $2.75 price target despite negative profitability metrics.
The stock presents high-risk biotech speculation with potential upside dependent on FDA approval. Current valuation metrics (P/S 961.51) reflect speculative optimism rather than fundamentals. Major risks include cash burn (-$21.5M net cash flow), regulatory uncertainty, and competitive pressures. Successful commercialization of INO-3107 is critical for viability.
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nordic American Tankers Limited Common Stock
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →
